Reviva Pharmaceuticals has announced positive data from a Phase II trial of RP5063 to treat schizophrenia and schizoaffective disorder.

The randomised double-blind study was designed to evaluate RP5063’s efficacy, safety and tolerability profile in male and female schizophrenia patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Massachusetts General Hospital schizophrenia programme director and Harvard Medical School associate professor Dr Oliver Freudenreich said; "These results confirm that the dopamine serotonin stabiliser RP5063 has great promise since it is both effective and with a potentially excellent safety profile particularly with regards to metabolic problems."

The placebo-controlled, dose ranging, multi-centre study enrolled a total of 234 schizophrenia patients from the US, Asia and Europe.

"The randomised double-blind study was designed to evaluate RP5063’s efficacy, safety and tolerability profile in male and female schizophrenia patients."

Patients were randomised to receive either RP5063 at doses of 15mg, 30mg or 50mg/day, placebo or a control arm of aripiprazole (15mg).

Overall broad efficacy of the candidate was established across the Positive and Negative Syndrome Scale total scores, in addition to subscales for Positive Negative and General Psychopathology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An efficacy in the Clinical Global Impression Severity Scale was also noted.

RP5063 was well-tolerated with favourable safety profile in the study.

Clinically vital differences in systematic side effects between RP5063 and placebo such as motor function, cardiac metabolic parameters or in prolactin-related sexual problems were not identified.

No change was observed in normal blood chemistries haematology or urine parameters.

CRI Lifetree Philadelphia Research Center principal investigator Dr Mark Novitsky said; "These results confirm that RP5063 promises to be a ‘best in class’ dopamine serotonin stabiliser that has the potential to improve the treatment of schizophrenia and schizoaffective disorder filling a much unmet medical need."